Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 26:12:79-89.
doi: 10.2147/ITT.S390023. eCollection 2023.

Towards Early Diagnosis of Mixed Connective Tissue Disease: Updated Perspectives

Chiara Alfia Ferrara  1 , Gaetano La Rocca  2 , Giuseppe Ielo  1 , Alessandro Libra  1 , Gianluca Sambataro  1
Affiliations
Review

Towards Early Diagnosis of Mixed Connective Tissue Disease: Updated Perspectives

Chiara Alfia Ferrara et al. Immunotargets Ther. .

Abstract

Mixed Connective Tissue Disease (MCTD) is an autoimmune disease first described by Sharp et al in 1972, characterized by the presence of anti-Ribonucleoprotein antibodies directed against the U1 complex (anti-U1RNP). The condition shares clinical characteristics with Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Systemic Sclerosis. Diagnosis is quite difficult due to its rarity, the lack of validated classification criteria, and its heterogeneous clinical presentation. While in the early stages its nuanced clinical features might lead to it being incorrectly classified as other Connective Tissue Diseases (CTDs) or even not recognized, in cases of longstanding disease its classification as a CTD is clear but challenging to discriminate from overlap syndromes. MCTD should be considered a distinct entity due to the presence of a specific genetic substrate and the presence of the high titer of a specific autoantibody, anti-U1RNP, present in all the commercial kits for Extractable Nuclear Antigens, and almost always associated with Antinuclear Antibody positivity with a coarse speckled pattern. Except for anti-U1RNP, no specific biomarkers are available to guide clinicians to a correct classification of MCTD, which is arrived at by the association of clinical, serological and instrumental evaluation. In the first stages, the disease is mainly characterized by Raynaud's phenomenon, inflammatory arthritis, puffy fingers, myalgia and/or myositis, and rarely, trigeminal neuropathy. Longstanding disease is generally associated with the development of Pulmonary Hypertension and Interstitial Lung Disease, which are the two main causes of mortality in MCTD. The aim of this review is to summarize current knowledge on the early recognition of MCTD.

Keywords: Raynaud’s phenomenon; anti-RNP; diagnosis; inflammatory arthritis; mixed connective tissue disease; nailfold videocapillaroscopy.

PubMed Disclaimer

Conflict of interest statement

Gianluca Sambataro received honoraria from Boheringer Ingelheim, outside of the submitted work. Gaetano La Rocca, Chiara Alfia Ferrara, Giuseppe Ielo, and Alessandro Libra have no conflicts of interest to declare for this work.

Figures

Figure 1
Figure 1
Fibrotic Nonspecific Interstitial Pneumonia in a patient with a longstanding Mixed Connective Tissue Disease. The pattern is characterized by diffuse Ground Glass Opacities (yellow arrow), subpleural sparing (blue arrow), and presence of traction bronchiectasis (red arrow).
Figure 2
Figure 2
Nailfold Videocapillaroscopy in a healthy subject (A) compared with a patient with Mixed Connective Tissue Disease (B–D). The pattern is characterized by the presence of multiple Giant Capillaries and neoangiogenesis.
See this image and copyright information in PMC

References

    1. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):149–159. doi:10.1016/0002-9343(72)90064-2 - DOI - PubMed
    1. Sharp GC. Diagnostic criteria for classification of MCTD. In: Kasukawa R, Sharp GC, editors. Mixed Connective Tissue Disease and Anti-Nuclear Antibodies. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division); 1987:23–30.
    1. Alarcón-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed Connective Tissue Disease and Antinuclear Antibodies. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division); 1987:33–40.
    1. Kasukawa R, Tojo T, Miyawaki S. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed Connective Tissue Disease and Anti-Nuclear Antibodies. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division); 1987:41–47.
    1. Kahn MF, Appelboom T. Syndrome de Sharp. In: Kahn MF, Peltier AP, Mayer O, Piette JC, editors. Les maladies systémiques. 3rd ed. Paris: Flammarion; 1991:545–556.